REPEAT: Seeing Machines loss narrows; Hansard profit falls
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
| Price | 82.50p on 21-01-2026 at 18:50:05 |
|---|---|
| Change | 0.00p 0% |
| Buy | 85.00p |
| Sell | 80.00p |
| Last Trade: | Buy 413.00 at 83.587p |
| Day's Volume: | 413 |
| Last Close: | 82.50p |
| Open: | 82.50p |
| ISIN: | GB00BMWLM973 |
| Day's Range | 82.50p - 82.50p |
| 52wk Range: | 35.40p - 97.50p |
| Market Capitalisation: | £31.15m |
| VWAP: | 83.587p |
| Shares in Issue: | 37.76m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Arecor Therape (AREC) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 413 | 83.587p | Ordinary |
13:01:17 - 21-Jan-26 |
| Buy* | 36 | 83.70p | Ordinary |
08:02:02 - 20-Jan-26 |
| Sell* | 5,000 | 81.50p | Ordinary |
16:33:42 - 19-Jan-26 |
| Buy* | 172 | 83.90p | Ordinary |
16:14:36 - 19-Jan-26 |
| Buy* | 5,992 | 83.95p | Ordinary |
16:06:04 - 19-Jan-26 |
| Buy* | 1,191 | 83.95p | Ordinary |
08:34:11 - 19-Jan-26 |
| Buy* | 1,314 | 84.00p | Ordinary |
12:48:25 - 16-Jan-26 |
| Sell* | 1,000 | 81.00p | Ordinary |
09:10:24 - 16-Jan-26 |
| Buy* | 117 | 85.00p | SI Trade |
10:01:33 - 15-Jan-26 |
| Sell* | 2 | 80.00p | SI Trade |
10:01:33 - 15-Jan-26 |
Arecor Therape (AREC) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 6th Jan 2026 2:01 pm | RNS | Fireside Panel Discussion on Diabetes sector |
| 9th Dec 2025 7:00 am | RNS | Arecor and Sequel Med Tech to host fireside panel |
| 17th Nov 2025 11:37 am | RNS | Holding(s) in Company |
| 11th Nov 2025 9:50 am | RNS | Holding(s) in Company |
| 4th Nov 2025 7:00 am | RNS | Enhanced IP Coverage: AT278 & Oral Peptide Program |
| 29th Sep 2025 7:00 am | RNS | Directorate Changes |
| 25th Sep 2025 7:00 am | RNS | Interim results for the six months to 30 June 2025 |
| 25th Sep 2025 7:00 am | RNS | Co-Development Agreement & Monetisation Deal |
| 24th Sep 2025 9:30 am | RNS | Notice of Interim Results |
| 4th Sep 2025 7:00 am | RNS | Positive FDA Feedback on Phase 2 Study Design |